The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes. METHODS: We included patients registered in the Swedish National Diabetes Register from 1998 through 2012 and followed them through 2014. Trends in deaths and cardiovascular events were estimated with Cox regression and standardized incidence rates. For each patient, controls who were matched for age, sex, and county were randomly selected from the general population. RESULTS: Among patients with type 1 diabetes, absolute changes during the study period in the incidence rates of sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.4 (95% confidence interval [CI], -56.1 to -6.7); death from cardiovascular disease, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); and hospitalization for cardiovascular disease, -45.7 (95% CI, -71.4 to -20.1). Absolute changes per 10,000 person-years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to -43.2); death from cardiovascular disease, -110.0 (95% CI, -128.9 to -91.1); death from coronary heart disease, -91.9 (95% CI, -108.9 to -75.0); and hospitalization for cardiovascular disease, -203.6 (95% CI, -230.9 to -176.3). Patients with type 1 diabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with type 2 diabetes had roughly 20% greater reduction than controls. Reductions in fatal outcomes were similar in patients with type 1 diabetes and controls, whereas patients with type 2 diabetes had smaller reductions in fatal outcomes than controls. CONCLUSIONS: In Sweden from 1998 through 2014, mortality and the incidence of cardiovascular outcomes declined substantially among persons with diabetes, although fatal outcomes declined less among those with type 2 diabetes than among controls. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Atherosclerotic cardiovascular disease (ASCVD) broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ASCVD broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
In the citing paper
“T2DM is common among patients with ASCVD or at the highest risk of CVD.The converse is also true: ASCVD is common in patients with T2DM.148”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“Diabetes is a well-established risk factor for ischaemic heart disease (IHD), and CAD accounts for 40-80% of deaths in patients with T2DM.148,359,381”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“These results were consistent across subgroups including those with and without diabetes or CKD.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“The primary outcome of worsening HF or CVD death was significantly reduced, 16.3% versus 21.2% for dapagliflozin compared with placebo (HR, 0.74; 95% CI, 0.65–0.85).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“Patients with T2DM are at high risk for ASCVD and HF compared with nondiabetic individuals (50,53).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“DAPA-HF was the first clinical trial of an SGLT2 inhibitor to assess HF events as the primary outcome and to include participants with and without diabetes (50).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. E. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 4,018
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,000
Chlabicz, M., Jamiołkowski, J., Paniczko, M., Sowa, P., Szpakowicz, M., Łapińska, M., Jurczuk, N., Kondraciuk, M., Ptaszyńska‐Kopczyńska, K., Raczkowski, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051364 · Cited by 15
Cano, A., Llauradó, G., Albert, L., Mazarico, I., Astiarraga, B., González-Sastre, M., Martínez, L., Fernández‐Veledo, S., Simó, R., Vendrell, J. J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072192 · Cited by 15
Slåtsve, K. B., Claudi, T., Lappegård, K. T., Jenum, A. K., Larsen, M., Cooper, J. G., Sandberg, S., & Berg, T. J. (2020) · Scandinavian Journal of Public Health · doi:10.1177/1403494820951004 · Cited by 15
Jeon, J. Y., Kim, S., Ha, K. H., Park, J. H., Park, B., Oh, C., & Han, S. J. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13397 · Cited by 15
Hart, L. C., Ferris, M., Nazareth, M. L., Faldowski, R. A., Rak, E. C., Hooper, S. R., Ndugga, M., & van Tilburg, M. A. L. (2020) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2020.08.010 · Cited by 15
Cao, L., Hou, M., Zhou, W., Sun, L. V., Shen, J., Chen, Y., Tang, Y., Wang, B., Li, X., & Lv, H. (2021) · Angiology · doi:10.1177/00033197211010096 · Cited by 15
The changing character of diabetes complications
Bellary, S. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00313-2 · Cited by 15
Eliasson, B., Ericsson, Å., Fridhammar, A., Nilsson, A., Persson, S., & Chubb, B. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00317-z · Cited by 14
Self-citationKleiner, A., Cum, B., Pisciotta, L., Cincione, R. I., Cogorno, L., Prigione, A., Tramacere, A., Vignati, A., Carmisciano, L., & Sukkar, S. G. (2022) · Nutrients · doi:10.3390/nu14153208 · Cited by 17
Chew, B.-H., Fernandez, A., & Sazlina, S.-G. (2018) · Psychology Research and Behavior Management · doi:10.2147/prbm.s117224 · Cited by 14
Arow, Z., Hornik‐Lurie, T., Hilu, R., Giladi, E., Arnson, Y., Assa, H. V., Assali, A. R., & Pereg, D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02874-7 · Cited by 15
Dyslipidaemia in Type 1 Diabetes: Molecular Mechanisms and Therapeutic Opportunities
O’Brien, S. T., Neylon, O. M., & O’Brien, T. (2021) · Biomedicines · doi:10.3390/biomedicines9070826 · Cited by 15
Linares, S. N., Beltrame, T., Galdino, G. A. M., Frade, M. C. M., Milan‐Mattos, J. C., Góis, M. D. O., Borghi‐Silva, A., de Biase, P. F., Manchado-Gobatto, F. D. B., Bagnato, V. S., et al. (2022) · Photonics · doi:10.3390/photonics9070481 · Cited by 14
Eliasson, B., Lyngfelt, L., Strömblad, S.-O., Franzén, S., & Eeg‐Olofsson, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-22932-4 · Cited by 14
Self-citationWei, Z., Huang, Z., Song, Z., Zhao, W., Zhao, D., Tan, Y., Chen, S., Yang, P., Li, Y., & Wu, S. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01102-0 · Cited by 14
Giménez‐Pérez, G., Viñals, C., Mata‐Cases, M., Vlacho, B., Real, J., Franch‐Nadal, J., Ortega, E., & Mauricio, D. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01917-1 · Cited by 14
Kwiendacz, H., Wijata, A. M., Nalepa, J., Piaśnik, J., Kulpa, J., Herba, M., Boczek, S., Kegler, K., Hendel, M., Irlik, K., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01938-w · Cited by 14
Yoon, S., Goh, H., Phang, J. K., Kwan, Y. H., & Low, L. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-47168-8 · Cited by 14
Janota, O., Mantovani, M., Kwiendacz, H., Irlik, K., Bucci, T., Lam, S. H. M., Huang, B., Alam, U., Boriani, G., Hendel, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02420-x · Cited by 14
Impact of dietary supplementation of glycocalyx precursors on vascular function in type 2 diabetes
Smith, J. A. H., Ramirez‐Perez, F. I., Burr, K., Gonzalez-Vallejo, J. D., Morales‐Quinones, M., McMillan, N. J., Ferreira‐Santos, L., Sharma, N., Foote, C. A., Martinez‐Lemus, L. A., et al. (2024) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00651.2024 · Cited by 14
Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes
Patel, K. V., Chunawala, Z. S., Verma, S., Segar, M. W., Garcia, K. R., Ndumele, C. E., Wang, T. J., Januzzi, J. L., Bayés‐Genís, A., Butler, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.004 · Cited by 14
González‐Cantú, A., Mireles-Zavala, L., Rodríguez-Romo, A., Olavide-Aguilar, E., la Garza-Hernández, N. E. D., & Romero-Ibarguengoitia, M. E. (2017) · Psychology Health & Medicine · doi:10.1080/13548506.2017.1363897 · Cited by 17
Work-loss years among people diagnosed with diabetes: a reappraisal from a life course perspective
von Bonsdorff, M. B., von Bonsdorff, M. E., Haanpää, M. L., Salonen, M. K., Mikkola, T. M., Kautiainen, H., & Eriksson, J. G. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1119-x · Cited by 14
Gjelsvik, B., Tran, A. T. N., Berg, T. J., Bakke, Å., Mdala, I., Nøkleby, K., Cooper, J. G., Claudi, T., Løvaas, K. F., Thue, G., et al. (2019) · BJGP Open · doi:10.3399/bjgpopen18x101636 · Cited by 15
Bakke, Å., Dalen, I., Thue, G., Cooper, J. G., Skeie, S., Berg, T. J., Jenum, A. K., Claudi, T., Løvaas, K. F., & Sandberg, S. (2019) · Diabetic Medicine · doi:10.1111/dme.14159 · Cited by 14
Schnell, O., Valensi, P. E., Standl, E., & Ceriello, A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.129 · Cited by 15
Gyldenkerne, C., Olesen, K. K. W., Thrane, P. G., Madsen, M., Thim, T., Würtz, M., Jensen, L. O., Raungaard, B., Poulsen, P. L., Bøtker, H. E., et al. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120941809 · Cited by 14
Gabler, M., Picker, N., Geier, S., Ley, L., Aberle, J., Lehrke, M., Martin, S., Riedl, M., & Wilke, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01024-y · Cited by 14
Jang, J. W., Kim, H., Kim, I., Lee, S. W., Jung, H. G., Hwang, K. S., Lee, J. H., Lee, G., Lee, D., & Yoon, D. S. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04541 · Cited by 15
Brinck, J. W., Hagström, E., Nåtman, J., Franzén, S., Eeg‐Olofsson, K., Nathanson, D., & Eliasson, B. (2022) · Diabetes Care · doi:10.2337/dc22-1025 · Cited by 14
Self-citationPetria, I., Albuquerque, S., Varoquaux, G. P., Vie, J.-J., Venteclef, N., Mohammedi, K., Roussel, R., Camoin, M., Perseghin, G., Velho, G., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01689-0 · Cited by 14
Amadid, H., Clemmensen, K. K. B., Vistisen, D., Persson, F., & Jørgensen, M. E. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01692-5 · Cited by 15
Falkentoft, A. C., Gerds, T. A., Zareini, B., Knop, F. K., Køber, L., Torp-Pedersen, C. T., Schou, M., Bruun, N. E., & Ruwald, A. (2023) · Diabetologia · doi:10.1007/s00125-023-05977-6 · Cited by 14
Jiang, M., Man, W., Zhang, X., Zhang, X.-H., Duan, Y. Z., Lin, J., Zhang, Y., Cao, Y., Wu, D.-X., Shu, X.-F., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00493-5 · Cited by 14
Kotsis, V., Jordan, J., Stabouli, S., Antza, C., Micić, D., Jelaković, B., Schlaich, M. P., Nilsson, P. M., Kreutz, R. H., Mancia, G., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002279 · Cited by 14
Polysaccharide from white kidney bean can improve hyperglycemia and hyperlipidemia in diabetic rats
Meng, J., Bai, Z., Huang, W., Liu, Y., Wang, P., Nie, S., & Huang, X. (2020) · Bioactive Carbohydrates and Dietary Fibre · doi:10.1016/j.bcdf.2020.100222 · Cited by 14
Shariat‐Madar, Z., & Mahdi, F. (2025) · Molecules · doi:10.3390/molecules30224448 · Cited by 15
Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes: Prevalence and Gender Differences
Vurallı, D., Jalilova, L., Alikaşifoğlu, A., Özön, Z. A., Gonc, E. N., & Kandemir, N. (2023) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2023.2023-12-12 · Cited by 14
Helmink, M. A. G., Hageman, S. H. J., Eliasson, B., Sattar, N. A., Visseren, F. L. J., Dorresteijn, J. A. N., Harris, K., Peters, S. A. E., Woodward, M., Szentkúti, P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15531 · Cited by 15
Self-citationLukman, H. Y., Aribisala, J. O., Akoonjee, A., Sulyman, A. O., Wudil, A., & Sabiu, S. (2024) · Scientific African · doi:10.1016/j.sciaf.2024.e02173 · Cited by 13
Electrocardiographic markers in patients with type 2 diabetes and the role of diabetes duration
Isaksen, J. L., Sivertsen, C. B., Jensen, C. Z., Graff, C., Linz, D., Ellervik, C., Jensen, M. T., Jørgensen, P. G., & Kanters, J. K. (2024) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2024.04.003 · Cited by 13
Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
Kim, J. H., Lee, J., Han, K., Kim, J., & Kwon, H. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0275 · Cited by 13
Análisis de las hospitalizaciones por enfermedad cardiovascular en población diabética en España
Zapatero, A., Gómez‐Huelgas, R., Canora, J., Muñoz, J. E., Romero-Sánchez, M., Méndez‐Bailón, M., Marco-Martínez, J., & Barba, R. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2018.09.012 · Cited by 13
Gholamhoseinian, A., Abbasalipourkabir, R., Ziamajidi, N., Sayadi, M., & Sayadi, K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117393 · Cited by 13
Jermendy, G., Kiss, Z., Rokszin, G., Fábián, I., Wittmann, I., & Kempler, P. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108134 · Cited by 13
Diabetes and CVD Risk: Special Considerations in African Americans Related to Care
Wittwer, J. A., Golden, S. H., & Joseph, J. J. (2020) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-020-00648-2 · Cited by 13
Ushigome, E., Kitagawa, N., Kitagawa, N., Tanaka, T., Hasegawa, G., Ohnishi, M., Tsunoda, S., Ushigome, H., Yokota, I., Nakamura, N., et al. (2020) · Hypertension Research · doi:10.1038/s41440-020-00584-z · Cited by 13
Höhn, A., Jeyam, A., Caparrotta, T. M., McGurnaghan, S. J., O’Reilly, J. E., Blackbourn, L. A. K., McCrimmon, R. J., Leese, G., McKnight, J. A., Kennon, B., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05394-7 · Cited by 13
Self-citationAlkhezi, O. S., Alsuhaibani, H. A., Alhadyab, A. A., AlFaifi, M., Alomrani, B., Aldossary, A., & Alfayez, O. M. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.04.005 · Cited by 14
Zweck, E., Karschnia, M., Scheiber, D., Heidecke, H., Dechend, R., Barthuber, C., Kaufmann, S. G., Kelm, M., Roden, M., Westenfeld, R., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14293 · Cited by 13
Corpeleijn, W. E., de Waal, W. J., Schipper, H. S., & Wiegman, A. (2023) · Diabetologia · doi:10.1007/s00125-023-06041-z · Cited by 15
Interaction between type 2 diabetes polygenic risk and physical activity on cardiovascular outcomes
Lee, C.-L., Yamada, T., Liu, W.-J., Hara, K., Yanagimoto, S., & Hiraike, Y. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae075 · Cited by 13
Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives
de Vries, J. K., Levin, A., Loud, F. C., Adler, A., Mayer, G. J., & Pena, M. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13412 · Cited by 13
Karlsson, S. A., Eliasson, B., Franzén, S., Miftaraj, M., Svensson, J., & Sundell, K. A. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000639 · Cited by 13
Self-citationTseng, J., Chen, H., Huang, K., Hsu, S.-P., & Chen, C. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13951 · Cited by 13
Shi, M., Tang, R., Huang, F., Zhong, T., Chen, Y., Li, X., & Zhou, Z. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3423 · Cited by 13
Long-Term Glycemic Variability Is Associated With Arterial Stiffness in Chinese Adults
Zhang, Y., Wu, S., Li, M., Wang, T., Xu, M., Lu, J., Wang, S., Zhang, J., Bi, Y., Wang, W., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.711540 · Cited by 12
Samidurai, A., Olex, A. L., Ockaili, R. A., Kraskauskas, D., Roh, S. K., Kukreja, R. C., & Das, A. (2023) · Cells · doi:10.3390/cells12242820 · Cited by 12
Andersson, K., Halling, A., & Agvall, B. (2024) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2024.2329215 · Cited by 12
Ghusn, W., Ma, P., Vierkant, R. A., Mundi, M. S., Fehervari, M., Ikemiya, K., Hage, K., Acosta, A. J., Camilleri, M., Dayyeh, B. A., et al. (2025) · Annals of Surgery · doi:10.1097/sla.0000000000006656 · Cited by 12
Thymosin β4-mediated protective effects in the heart
Hinkel, R., Klett, K., Bähr, A., & Kupatt, C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1490409 · Cited by 12
Holstein, A., Titze, U., & Heß, C. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0752-0028 · Cited by 14
Patients with type 1 diabetes in a tertiary setting do not attain recommended lipid targets
Lan, N. S. R., Yeap, B. B., Bell, D. A., Watts, G. F., & Fegan, P. G. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.12.002 · Cited by 12
Ruiz, S., Amor, A. J., Pané, A., Andújar, A. M., Montagud‐Marrahí, E., Ventura‐Aguiar, P., Ferrer, J., & Esmatjes, E. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108135 · Cited by 13
Lu, C., Chang, Y., Martini, S., Chang, M., & Li, C. (2020) · Journal of Epidemiology · doi:10.2188/jea.je20200026 · Cited by 12
Saeed, M., Tapia, G., Ariansen, I., Stene, L. C., Seljeflot, I., Tell, G. S., Skrivarhaug, T., & Joner, G. (2021) · Diabetes Care · doi:10.2337/dc20-1712 · Cited by 12
Weber, D. R. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000638 · Cited by 12
Plakht, Y., Hirsch, Y. E., Shiyovich, A., Tailakh, M. A., Liberty, I. F., & Gilutz, H. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109117 · Cited by 12
Aulanni’am, A., Wuragil, D. K., Susanto, H., Herawati, A., Nugroho, Y., fajri, W. N. L., Putri, P. F., Susiati, S., Purnomo, J. D. T., Taufiq, A., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08695 · Cited by 13
Zhang, L., Yang, H., & Yang, P. C. (2022) · Applied Bionics and Biomechanics · doi:10.1155/2022/4154426 · Cited by 12
RetractedShah, H., Moreno, L. O., Morieri, M. L., Tang, Y., Mendonça, C., Jobe, J. M., Thacker, J. B., Mitri, J., Monti, S., Niewczas, M. A., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1789 · Cited by 12
Höskuldsdóttir, G., Franzén, S., Eeg‐Olofsson, K., & Eliasson, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-16135-0 · Cited by 14
Self-citationRisk factors for decline in renal function among young adults with type 1 diabetes
Schwandt, A., Bergis, D., Denkinger, M. D., Gollisch, K. S. C., Sandig, D., Stingl, H., Zimny, S., & Holl, R. W. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.07.007 · Cited by 12
Addressing Lifestyle Management During Visits Involving Patients with Prediabetes: NAMCS 2013–2015
Wu, J., Ward, E. D., & Lu, K. (2018) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4724-z · Cited by 12
Huang, J., Liu, Y., Liu, T., Chang, Y., Chen, T., & Li, X. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01197h · Cited by 12
Liu, A., Li, K., Xu, L., Si, M., Teng, G., Li, G., Xue, J., Liang, S., & Song, W. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00761-w · Cited by 12
Amor, A. J., Vinagre, I., Valverde, M., Urquizu, X., Meler, E., López, E., Alonso-Carril, N., Pané, A., Giménez, M., Codina, L., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108548 · Cited by 12
Melo, M., Gavina, C., Silva‐Nunes, J., Andrade, L., & Carvalho, D. M. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00698-5 · Cited by 12
Cavallari, I., Maddaloni, E., Pieralice, S., Mulè, M. T., Buzzetti, R., Ussia, G. P., Pozzilli, P., & Grigioni, F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa427 · Cited by 12
Nieuwkerk, A. C. V., Santos, R. B., Blanco, R., Tchétché, D., de Brito, F. S., Barbanti, M., Kornowski, R., Latib, A., D’Onofrio, A., Ribichini, F. L., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01654-x · Cited by 11
Gay, H. C., Yu, J., Persell, S. D., Linder, J. A., Srivastava, A., Isakova, T., Huffman, M. D., Khan, S. S., Mutharasan, R. K., Petito, L. C., et al. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.041 · Cited by 11
Lucero, K. S., Larkin, A. T., Zakharkin, S. O., Wysham, C., & Anderson, J. E. (2023) · JMIR Medical Education · doi:10.2196/48586 · Cited by 11
Niu, S., Alkhuzam, K. A., Guan, D., Jiao, T., Shi, L., Fonseca, V. A., Laiteerapong, N., Ali, M. K., Schatz, D., Guo, J. S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15332 · Cited by 11
Yang, L., Gabriel, N., Bian, J., Bilello, L. A., Wright, D. R., Hernandez, I., & Guo, J. S. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.11.1242 · Cited by 11
Katsuyama, H., Hakoshima, M., Heshiki, T., Iida, S., Adachi, H., & Yanai, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111752 · Cited by 11
Kim, S., Kim, G., Cho, S. H., Oh, R., Kim, J. Y., Lee, Y., Jin, S., Hur, K. Y., & Kim, J. H. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116228 · Cited by 11
Approach to Lipid Management in the Patient With Diabetes
Kim, S. J., & Subramanian, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf018 · Cited by 12
Mesa, A., Franch‐Nadal, J., Navas, E., & Mauricio, D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02791-9 · Cited by 14
Salle, L., Julla, J., Fagherazzi, G., Gourdy, P., Parente, E. B., Hanaire, H. P., Tatulashvili, S., Disse, E., Franc, S., Hadjadj, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02789-3 · Cited by 11
Dastjerdi, P., Mohammadi, N. S. H., Anaraki, N., Rahmati, S., Nikfar, R., Momeni, S., Zafarmandi, S., Saeidi, S., Askari, M. K., Hosseini, S., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01900-8 · Cited by 11
Costacou, T., & Orchard, T. J. (2019) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000164 · Cited by 11
Ghosal, S., Sinha, B., Ved, J., & Biswas, M. (2020) · Indian Heart Journal · doi:10.1016/j.ihj.2020.03.010 · Cited by 11
Johansson, I., & Norhammar, A. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108822 · Cited by 11
Kofod, D. H., Almdal, T., Sørensen, V. R., Feldt‐Rasmussen, B., & Hornum, M. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.305 · Cited by 11
Nwosu, B. U., Parajuli, S., Khatri, K., Jasmin, G., Al‐Halbouni, L., & Lee, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.705565 · Cited by 11
Stevens, S. R., Segar, M. W., Pandey, A., Lokhnygina, Y. V., Green, J. B., McGuire, D. K., Standl, E., Peterson, E. D., & Holman, R. R. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01603-8 · Cited by 11
Self-citationAssociations between migraine and major cardiovascular events in type 2 diabetes mellitus
Cheon, D. Y., Han, K., Yang, Y., Kim, Y., Lee, S., Kim, C., Sohn, J., Oh, M. S., Lee, B., Lee, M., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01705-3 · Cited by 11
Karmali, R., Sipko, J., Majid, M., & Bruemmer, D. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01866-x · Cited by 11
Omachi, T., Ohara, M., Fujikawa, T., Kohata, Y., Sugita, H., Irie, S., Terasaki, M., Mori, Y., Fukui, T., & Yamagishi, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01493-3 · Cited by 11
Rawshani, A., Eliasson, B., Borén, J., Sattar, N. A., Bhatt, D. L., El-Khalili, L., Nordanstig, J., Avdic, T., Beckman, J. A., Gerstein, H. C., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100888 · Cited by 12
Self-citation
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- University of Glasgow (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-04-13
- Volume
- 376
- Issue
- 15
- Pages
- 1407-1418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2606281213
- Cited by
- 1,389
- References
- 37
- Citations by year
- 2026: 100 · 2025: 144 · 2024: 163 · 2023: 149 · 2022: 184 · 2021: 176 · 2020: 196 · 2019: 140 · 2018: 95 · 2017: 39
- FWCI
- 101.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, type 2 diabetes, cardiovascular disease, mortality, coronary artery disease, cardiovascular hospitalization, Sweden, diabetes registry, standardized incidence rate
- MeSH terms
- Adolescent, Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Male, Middle Aged, Mortality, Registries, Risk Factors, Sweden, Incidence, Proportional Hazards Models, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
